Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

To commemorate the 25th anniversary of Denali, GMC is offering customers a special 25th Anniversary Denali Package available ...

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

After Denali Therapeutics (DNLI) reported DNL343 did not meet the primary or key secondary endpoints in the Phase 2/3 HEALEY trial in ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price ...